Kivisäkk, Pia
Carlyle, Becky C.
Sweeney, Thadryan
Quinn, James P.
Ramirez, Christopher E.
Trombetta, Bianca A.
Mendes, Muriel
Brock, Mary
Rubel, Carrie
Czerkowicz, Julie
Graham, Danielle
Arnold, Steven E.
Article History
Received: 21 December 2021
Accepted: 8 April 2022
First Online: 23 April 2022
Declarations
:
: The study was approved by the Institutional Review Board of Mass General Brigham (2015P000221 and 2018P001989), and all participants provided written informed consent for use of their CSF in this research.
: Not applicable.
: S. Arnold has received honoraria and/or travel expenses for lectures from Abbvie, Eisai, and Biogen and has served on scientific advisory boards of Corte, has received consulting fees from Athira, Cassava, Cognito Therapeutics, EIP Pharma and Orthogonal Neuroscience, and has received research grant support from NIH, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, Abbvie, Amylyx, EIP Pharma, Merck, Janssen/Johnson & Johnson, Novartis, and vTv. M. Mendes and M. Brock are paid employees of Quanterix Corporation. C. Rubel, J. Czerkowicz, and D. Graham are paid employees of Biogen. The other authors report no declaration of interest.